Israel Active

Israel’s Quai.MD is developing an AI- platform that improves hospital patient care, reduces costs and saves doctors’ time. The process is tailored to the patient and hospital. Partners include Mayo Clinic & MUSC. Initial focus is the diagnosis of patients with chest pain.

The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see ) as a treatment for Hematopoietic Acute Radiation Syndrome - a deadly disease that can result from nuclear disasters and radiation exposure.

Israel’s ImPact Biotech has received Orphan treatment designation from the US FDA for its Padeliporfin VTP in Pancreatic Cancer. ImPact stands for IMmune Photo Activated Cancer Treatment and VTP is Vascular Targeted Photodynamic therapy.

It wasn’t long ago since the genome was fully decoded. Now, Israel’s C2i Genomics (see previously) has teamed up with Tel Aviv’s Sourasky (Ichilov) Medical Center take blood test data and perform whole genome minimal residual disease (MRD) testing to detect recurring cancer early.

Dr Cezar J. Mizrahi of Jerusalem’s Shaare Zedek Medical Center has performed the world’s first Augmented Reality-assisted robotic spinal surgery on a patient with an unstable spine fracture. Dr Mizrahi previously (see ) performed the world’s first robot-assisted lumbar spine fusion.

Israel’s Edity Therapeutics reprograms immune cells to recognize tumors that hide from the body’s regular immune system. Edity’s ED 007 cell therapy inflames these tumors, triggering the body’s own immune system to kill the cancer without risk of side effects or rejection.

Local mental health therapists at the Jewish National Fund-USA’s Eshkol Resilience Center in Sderot provide support for residents of the Gaza Envelope region.  They help their community cope with difficult times in one of the fastest-growing regions in Israel.

United Hatzalah, Lahak Aviation and Sheba Medical Center together have launched a pilot service to bring cancer patients from remote parts of Israel to hospital for treatment. Previous dangerous and stressful 3–4-hour journeys are reduced to a safe, comfortable 40-minutes.

Pulmonary Embolism (PE) is the third leading cause of cardiovascular-related death and the number one cause of preventable hospital death. Israel’s Althea Medical is developing an over-the-wire medical device that physicians can use to remove blood clots quickly and safely from arteries in the lung.

EGFR inhibitors are common treatments for cancer but cause severe skin problems that cannot be fully alleviated. Israel’s EMRIS is developing a topical solution to block EGFRi monoclonal antibodies and allow the patient to continue treatment without the debilitating side effects.